Showing 1761-1770 of 3239 results for "".
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to man
- Caliber Imaging & Diagnostics Names Daniel Koon to Director of Global Sales Supporthttps://practicaldermatology.com/news/20140314-caliber_imaging__diagnostics_names_daniel_koon_to_director_of_global_sales_support/2459316/Caliber Imaging & Diagnostics, formerly Lucid, Inc., named Daniel Koon to Director of Global Sales Support, effective immediately. Mr. Koon most recently served as Caliber I.D.'s Research Sales Manager. Mr. Koon has experience in international sales
- Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officerhttps://practicaldermatology.com/news/20140305-aquavit_pharmaceuticals_appoints_david_j_goldberg_as_chief_medical_officer/2459324/Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit,
- Promius Pharma, LLC Introduces Dr. Reddy's Authorized Generic Producthttps://practicaldermatology.com/news/20140225-promius_pharma_llc_introduces_dr_reddys__authorized_generic_product/2459331/Promius Pharma, LLC, launched its first Authorized Generic (AG) of Cloderm® Cream through its parent company Dr. Reddy's Laboratories on February 14. The AG is identical in formulation to Cloderm® Cream and will provide all the similar benefits, while increasing access and reducing pharmacy call
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope® Systems From European Distributor MAVIG GmbHhttps://practicaldermatology.com/news/20140114-caliber_imaging__diagnostics_receives_14_million_order_for_vivascope_systems_from_european_distributor_mavig_gmbh/2459373/Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe f
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- AAD Issues New Guidelines for Diagnosis and Assessment of Atopic Dermatitishttps://practicaldermatology.com/news/20131204-aad_issues_new_guidelines_for_diagnosis_and_assessment_of_atopic_dermatitis/2459399/The American Academy of Dermatology (AAD) recently announced the release of its new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy, re